News & Updates
Showing Cardiology articles
Showing

SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality
Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.

1-year mortality elevated after procedural/spontaneous myocardial infarction
A significantly higher 1-year mortality is seen following procedural myocardial infarction (pMI) and spontaneous MI (spMI) with troponin peak >35x the upper reference level (URL), reports a study. On the other hand, only spMI demonstrates a significant influence on mortality for troponin levels ≤35x.

CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.





